In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education. As the field of RSV prevention continues to grow, pediatricians face both new ...

In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration. As RSV prevention tools expanded, clinicians faced new ...

The new-look Advisory Committee on Immunization Practices (ACIP) will meet on June 25 and 26, 2025, for the first time since Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. replaced ...

In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management. Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young ...

AAP updates clinical guidance to help pediatricians navigate genetic evaluation of children with global developmental delay or intellectual disability.

Michael O. Daines, MD, outlines key diagnostic criteria and treatment challenges for pediatric acute-onset neuropsychiatric syndrome (PANS), emphasizing the need for multidisciplinary care and ...

The FDA has accepted a new drug application (NDA) for epinephrine sublingual film (Anaphylm; Aquestive Therapeutics) to treat type 1 allergic reactions, including anaphylaxis. With the acceptance of ...

In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).

Though the decision will not meet the June 17, 2025, target date, the federal agency anticipates a decision within approximately 4 weeks.

Childhood adversity may raise endometriosis risk, with exposure to violence linked to a twofold increase, a Swedish study of 1.3M women finds.

Frequent exposure to cannabis and e-cigarette posts on social media is linked to increased teen cannabis and dual substance use, according to a study published in JAMA.

On June 18, Biogen announced the dosing of participants in the BRAVE study (NCT06953583), a global phase 3 clinical trial evaluating omaveloxolone (Skyclarys) in children aged 2 to younger than 16 ...